---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019864"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:53:41.790144+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q1 revenue up 55% to $27.9M; raises FY2024 revenue guidance to $116M-$120M

## Summary
- Revenue of $27.9M, up 55% YoY from $17.9M.
- Net loss of $4.4M ($0.03 per share) vs $2.1M loss in prior year.
- Positive Adjusted EBITDA of $0.1M vs -$0.3M a year ago.
- Gross margin improved 340 bps to 62.1%.
- Full year 2024 revenue guidance raised to $116M-$120M from $112M-$116M.

## SEC filing metadata
- accession: 0001493152-24-019864
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019864
- JSON: https://secwatch.observer/filing/0001493152-24-019864.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019864.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $27.9 million, net income $4.3 million, or $0.03 per share, EPS $0.03 per share. Guidance raised.
  - Period: first quarter ended March 31, 2024
  - Revenue: $27.9 million
  - Net income: $4.3 million, or $0.03 per share
  - EPS: $0.03 per share
  - Guidance: raised
  - Result: reported results
  source text: treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights ● Revenue of $27.9 million, up 55%, compared to the prior year quarter ● Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter ● Net loss of $4.4 million compared to $2.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm
- Earnings Releases
  Xtant Medical Holdings, Inc. reported full year 2024 results: revenue $116 million to $120 million. Guidance raised.
  - Period: full year 2024
  - Revenue: $116 million to $120 million
  - Guidance: raised
  - Result: guidance update
  source text: Xtant Medical raises its expectation for full year 2024 revenue to $116 million to $120 million, up from the Company’s prior guidance of $112 million to $116 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.